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Abstract
Introduction: High levels of adherence to antiretroviral therapy (ART) are central to HIV management. The objective of this study
was to compare multiple measures of adherence and investigate factors associated with adherence among HIV-infected children
in western Kenya.
Methods: We evaluated ART adherence prospectively for six months among HIV-infected children aged 514 years attending
a large outpatient HIV clinic in Kenya. Adherence was reported using caregiver report, plasma drug concentrations and
Medication Event Monitoring Systems (MEMS†). Kappa statistics were used to compare adherence estimates with MEMS†.
Logistic regression analyses were performed to assess the association between child, caregiver and household characteristics
with dichotomized adherence (MEMS† adherence ]90% vs. B90%) and MEMS† treatment interruptions of ]48 hours. Odds
ratios (ORs) and 95% confidence intervals (95% CIs) were calculated.
Results: Among 191 children, mean age at baseline was 8.2 years and 55% were female. Median adherence by MEMS†
was 96.3% and improved over the course of follow-up (pB0.01), although 49.5% of children had at least one MEMS† treat-
ment interruption of ]48 hours. Adherence estimates were highest by caregiver report, and there was poor agreement
between MEMS† and other adherence measures (Kappa statistics 0.040.37). In multivariable logistic regression, only
caregiver-reported missed doses in the past 30 days (OR 1.25, 95% CI 1.141.39), late doses in the past seven days
(OR 1.14, 95% CI 1.051.22) and caregiver-reported problems with getting the child to take ART (OR 1.10, 95% CI 1.011.20)
were significantly associated with dichotomized MEMS† adherence. The caregivers reporting that ART made the child sick
(OR 1.12, 95% CI 1.011.25) and reporting difficulties in the community that made giving ART more difficult (e.g. stigma)
(OR 1.14, 95% CI 1.021.27) were significantly associated with MEMS† treatment interruptions in multivariable logistic
regression.
Conclusions: Non-adherence in the form of missed and late doses, treatment interruptions of more than 48 hours and sub-
therapeutic drug levels were common in this cohort. Adherence varied significantly by adherence measure, suggesting that
additional validation of adherence measures is needed. Few factors were consistently associated with non-adherence or
treatment interruptions.
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Introduction
The advent of antiretroviral therapy (ART) has significantly
improved the long-term survival of HIV-infected children [15],
and good outcomes rely on high rates of adherence to therapy
[69]. The International Association of Physicians in AIDS Care
recommends routine monitoring of adherence to ART for all
patients in clinical settings to guide clinical decision making,
prevent drug resistance, and evaluate adherence interven-
tions, but there are no specific recommendations for monitor-
ing adherence in paediatric HIV [10].
Recent studies suggest that children in low- and middle-
income countries (LMICs) have similar or better rates of ART
adherence compared to children from high-income countries;
however, most estimates of paediatric adherence in LMICs
come from heterogeneous and unvalidated measures [1113].
Adherence assessment by caregiver reports is commonly used
in studies reporting ART among children and is consistently
higher than adherence by other measures like pill count or
pharmacy refill, suggesting that caregivers likely overestimate
their child’s adherence [12,13]. Electronic dose monitoring
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with technologies like Medication Event Monitoring Systems
(MEMS†)  bottle caps fitted with a microchip that records
the time and date of each bottle opening  is most con-
sistently associated with virological outcomes [14,15] but
is often too expensive for routine use in LMICs outside of
research settings [16].
For children in LMICs who have limited access to second-
and third-line treatment options, the preservation of first-line
regimens through high rates of adherence is particularly im-
portant for survival into adolescence and adulthood [17,18].
Despite the importance of adherence to ART, children in
LMICs often face multiple and complex barriers to achieving
optimal adherence, and there are few data to inform adher-
ence interventions [19]. A better understanding of factors
that are associated with adherence in HIV-infected children
is critical to the design and implementation of effective
interventions.
The Academic Model Providing Access to Healthcare (AMPATH)
provides comprehensive HIV care for over 5000 HIV-infected
children (B15 years of age) on ART in western Kenya. We
conducted a cohort study to describe adherence to ART
among children in this setting. Our objective was twofold:
1) to describe adherence to ART using multiple measures and
compare routine measures (e.g. caregiver-reported adher-
ence) to MEMS†, and 2) investigate factors associated with
poor adherence. This study adds to the literature on best prac-
tices for measuring adherence to ART among HIV-infected
children in LMICs, and it may be used to inform adherence
interventions in this population.
Methods
Study design
We conducted a prospective cohort study with 200 HIV-
infected children, 514 years of age and on ART and their
caregivers at AMPATH’s largest paediatric clinic, which is
located at Moi Teaching and Referral Hospital (MTRH) in
Eldoret  the fifth largest city in Kenya. Participants were
followed for six months and participated in monthly study
visits, which took place in a private room with study personnel.
Study visits were scheduled on the same day as the child’s
routine clinical visit; after the child was seen by their regular
care provider, the child and caregiver would come to the
research office for their study visit. Demographic and clinical
characteristics were extracted by chart review. The study
was approved by the Institutional Review Board at Indiana
University School of Medicine in Indianapolis, Indiana, USA
and by the Institutional Research and Ethics Committee at
Moi University School of Medicine in Eldoret, Kenya.
Setting
AMPATH is a partnership between Moi University School
of Medicine, MTRH and a consortium of North American
academic medical centres led by Indiana University School of
Medicine. AMPATH provides free ART (first- and second-line
ART regimens only), primary care services and psychosocial
and nutritional support for children and adults.
Study participants
A convenience sample of 200 caregiver-child dyads were
identified by clinic and study personnel and referred for study
participation. The target sample size for this study was
selected to enable confident testing of up to 40 adherence
questionnaire items, which is reported elsewhere. For psycho-
metric analyses, at least five subjects per one item (with no
fewer than 100 participants) are considered necessary for
factor analysis [20]. Additionally, this sample size gave us
adequate power to detect a beta coefficient of 0.4 at a
0.05 significance level under the conservative assumption of
an error variance of 4 and independent variable standard
deviation of 1.
Eligible children were HIV-infected, 514 years old, on
either a nevirapine (NVP)- or efavirenz (EFV)-based first-line
ART regimen and enrolled in care at the AMPATH paediatric
outpatient clinic at MTRH. Fourteen was the maximum age
limit for enrolment because children older than this age are
routinely treated in the adult clinic. Enrolment was limited
to children on first-line ART containing NVP or EFV because
plasma drug concentrations were only available for these
drugs, and NVP or EFV is part of the standard first-line
paediatric regimen at AMPATH. The child’s current level of
adherence was not considered for study referral or selection;
however, it is possible that patients who had higher or lower
levels of adherence would be more likely to enrol. ‘‘Care-
giver’’ was defined as an individual who both accompanied
the child to clinical and study visits and had knowledge of
the child’s medication taking. While we encouraged the same
caregiver to come to all assessments, we did not exclude
different caregivers (e.g. mother versus grandfather) from
participating in the study assessments. Informed consent was
obtained for all caregivers, and assent for any child 10 years
and older, in line with standard AMPATH research protocols.
A small incentive was provided for participation to help cover
transportation costs and time.
Adherence measures
Monthly adherence assessments included caregiver-reported
adherence, drug concentrations and electronic medication
monitoring using MEMS† (AARDEX, Inc.). Caregiver-reported
adherence was assessed through a 48-item questionnaire
that included questions about missed or late doses, adher-
ence barriers, household characteristics and a visual analo-
gue scale (VAS) (adherence questionnaire provided under
‘‘Supplementary File’’). VAS was used to assess the number of
doses the child took over the last 30 days, with the caregivers
indicating doses taken on a horizontal line; the rightmost
side indicated that all doses were taken, and the leftmost
side indicated no doses taken. A trained research assistant
administered the questionnaire items verbally in Kiswahili
or English (depending on the caregiver’s language prefer-
ence) and then recorded the caregivers’ verbal responses on
a paper form.
The patients’ NVP or EFV was kept in a bottle with a
MEMS† cap for continuous electronic monitoring of medica-
tion dose timing throughout the study period. At enrolment,
patients were informed of the purpose of the MEMS† cap
and instructed in care of the cap and bottle. At each visit,
study staff downloaded data from the MEMS† caps and
shared these data with the caregivers and children by showing
them the computer display with the record of dose timing
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using PowerView software (Version 3.5.2; AARDEX, Inc.). The
downloading and sharing of dose timing from MEMS† were
conducted after the administration of the adherence ques-
tionnaires at every visit. Replacement MEMS† were given
to patients who reported damaged or lost MEMS†. MEMS†
events that occurred during the study assessments (e.g.
opening MEMS† to conduct pill counts) were censored for
analyses.
NVP and EFV drug concentrations were taken at two time
points (month 1 and month 4). Drug concentrations are
not available routinely at AMPATH, but were run for study
purposes in the AMPATH Reference Laboratory in Eldoret
using a rapid, automated enzyme immunoassay developed
by ARK Diagnostics (Sunnyvale, CA, USA). The ARK NVP-Test
and ARK EFV-Test are based on competitive binding to anti-
body between the drug in the sample and a drug-labelled
enzyme. Drug concentration was measured spectrophotome-
trically in terms of enzyme activity.
In the clinical care setting at AMPATH, the only routine
adherence measure for children consists of clinicians asking
either the caregiver or the child the following two questions:
‘‘During the last month, has the patient missed any medica-
tions?’’ and ‘‘During the last seven days, how many pills did
the patient take?’’ These adherence data were extracted for
study participants by chart review and compared to study-
administered adherence measures.
Data analysis
Adherence by caregiver-reported missed doses and VAS
adherence were dichotomized into ‘‘adherent’’ (defined as
no indication of missed doses in the recall period) versus
‘‘non-adherent’’ (defined as any indication of missed doses) at
each visit. Any indication of non-adherence was categorized as
‘‘non-adherent’’ because reports of non-adherence were so
scarce using these measures and caregiver reports generally
overestimate actual adherence [21]. Plasma drug concentra-
tions were categorized into therapeutic levels: sub-therapeutic
(NVP B3.0 mg/mL or EFV B1.0 mg/mL), therapeutic (NVP
3.07.6 mg/mL or EFV 1.04.0 mg/mL) or supra-therapeutic
(NVP 7.6 mg/mL or EFV 4.0 mg/mL) [22,23]. Adherence
by plasma drug concentration was dichotomized as ‘‘adher-
ent’’ (defined as therapeutic or supra-therapeutic) versus
‘‘non-adherent’’ (defined as a sub-therapeutic range). For
MEMS† adherence, mean and median adherence levels were
calculated by visit and across visits to estimate the percentage
of doses of NVP or EFV taken. MEMS† adherence was also
dichotomized as ‘‘adherent’’ (defined as ]90% of doses
taken by MEMS†) versus ‘‘non-adherent’’ (defined as B90%
of doses taken). While we recognize that 90% adherence may
not always be sufficient for viral suppression, MEMS† was
dichotomized at above or below 90% adherence for consis-
tency with previous studies [24,25]. Furthermore, studies
show that below this level of adherence, the risks for HIV
virological rebound and drug resistance are increased, parti-
cularly for older non-nucleoside reverse transcriptase inhibi-
tors like EFV and NVP [2628].
Univariable analyses with Student’s t-tests and Pearson’s
chi-square tests were used to explore relationships bet-
ween dichotomized MEMS† adherence and other adherence
measures as well as demographic, clinical and psychosocial
characteristics of the child and caregiver. Repeated-measures
logistic regression analyses using odds ratios (ORs) and 95%
confidence intervals (95% CIs) with and without adjusting
for baseline characteristics (gender, age and duration on ART)
were conducted using adherence data from each monthly
visit. Due to the high correlation between caregiver-reported
missed-doses variables using different recall periods (three-
day, seven-day and 30-day), inclusion into the multivariable
model was restricted to only one of these. The 30-day missed-
dose variable was chosen as it had the smallest p-value in
univariable models. We also used univariable and multi-
variable analyses (with and without adjusting for baseline
characteristics, as above) to investigate factors associated
withMEMS† treatment interruptions, defined as a single period
of 48 hours or greater with no recorded bottle opening. Kappa
statistics were calculated to compare adherence estimates
by the different methods of measurement to MEMS†. We
used MEMS† as the comparison adherence measure because
it is commonly used as the reference standard in studies
using multiple measures of adherence and best correlates
with virologic outcomes [2931]. All statistical analyses were
performed using SAS Version 9.3 (SAS Institute, Cary, NC).
Results
Study participant characteristics
Among 191 caregiver-child dyads followed for six months,
mean age of children at baseline was 8.2 years and 55% were
female. Weight-for-age Z (WAZ) scores indicated mild mal-
nutrition, with a mean WAZ score of 1.7. Mean duration on
ARTwas 2.3 years, with most children on NVP-based regimens
(77%). Children in this cohort had significant disease progres-
sion, with 54% at World Health Organization (WHO) Stage 3
at study start and a mean CD4 percentage of 26%. The most
common type of caregiver participant was the biological
mother of the child (63%), but there were also a number of
father (11%) and grandparent (7%) participants. For the vast
majority of children (90%), the same caregiver was present
for all adherence assessments during the study period.
Caregivers reported high levels of food insecurity (68%) and
difficulties with transportation to clinic (84%). There were
17 participants (9%) who had to have their MEMS† replaced
during the study period due to damage or MEMS† not fun-
ctioning properly. In univariable analyses, there was no sig-
nificant difference in baseline demographic and clinical factors
between children who were always adherent during the
study period (MEMS† adherence at every month 90%)
and children who were non-adherent at least once (MEMS†
adherence B90% for at least one month) (Table 1).
Adherence by multiple measures
Mean adherence by MEMS† was 87% (median adherence by
MEMS† was 96%) and improved significantly over the course
of the study; while only 51% achieved MEMS† adherence
]90% at month 1, 70% did so by month 6. Treatment
interruptions were common; 49% of children had at least one
MEMS† treatment interruption of ]48 hours (with a median
of 3 MEMS† treatment interruptions per child over the
course of the study). Adherence by caregiver-reported missed
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doses was higher using the three-day recall item (92% re-
ported no missed doses) and seven-day recall (92% reported
no missed doses) compared to the 30-day recall item (83%
reported no missed doses). Caregivers reported even higher
adherence by VAS (94% reported no missed doses). In con-
trast to MEMS†, caregiver-reported missed doses generally
showed consistent or decreasing adherence across the study
period (Figure 1). Fourteen per cent of children on NVP and
27% on EFV had sub-therapeutic drug levels, whereas 59%
of children on NVP and 23% on EFV had supra-therapeutic
drug levels (Table 2). Caregiver-reported missed doses to
clinicians at routine clinic visits suggested the highest rates
of adherence (97% reported no missed doses).
Agreement between adherence measures
There was poor agreement between dichotomized MEMS†
and other adherence measures, but most measures did show
a statistically significant association with MEMS† (Table 3).
Table 1. Caregiver-child dyad characteristics by MEMS† adherent group
Overall
Adherent (MEMS† 90%
doses taken at every visit)
Ever non-adherent (MEMS†
B90% doses taken at any visit)
Characteristic N191 N56 N134 p
Child characteristics
Mean age (years) 8.2 (3.3) 8.3 (3.1) 8.1 (3.3) 0.70
Female 105 (55%) 29 (52%) 76 (57%) 0.53
Mean weight-for-age Z (WAZ) score 1.7 (1.3)a 1.7 (1.2) 1.7 (1.3) 0.80
Mean ART duration (years) 2.3 (1.9) 2.6 (1.8) 2.2 (1.8) 0.18
ART regimen
NVP 148 (77%) 47 (84%) 101 (74%) 0.26
EFV 43 (22%) 9 (16%) 34 (25%)
NVP/EFV (both) 2 (1%) 0 (0%) 2 (1%)
Mean CD4% 26% (11%) 30% (9%) 25% (11%) 0.06
WHO Stage
1 34 (18%) 11 (20%) 23 (17%) 0.50
2 32 (17%) 11 (20%) 20 (15%)
3 104 (54%) 31 (55%) 75 (55%)
4 18 (9%) 3 (5%) 15 (11%)
Not answered 3 (2%) 0 (0%) 3 (2%)
Disclosure status
Child disclosed 44 (23%) 10 (18%) 34 (25%) 0.26
Caregiver and/or family characteristics
Caregiver relationship to child
Mother 121 (63%) 32 (57%) 88 (66%) 0.14
Father 21 (11%) 7 (13%) 14 (10%)
Sibling 3 (2%) 0 (0%) 3 (2%)
Grandparent 13 (7%) 3 (5%) 10 (7%)
Non-relative 7 (4%) 5 (9%) 2 (1%)
Other 26 (14%) 9 (16%) 17 (13%)
Individuals who give the child ARTb
Mother 160 (84%) 45 (80%) 114 (85%) 0.42
Father 68 (36%) 21 (38%) 46 (34%) 0.68
Sibling 80 (42%) 18 (32%) 62 (46%) 0.07
Other relative 68 (36%) 20 (36%) 48 (36%) 0.98
Child took own 60 (31%) 13 (23%) 47 (35%) 0.11
Caregiver employed outside the home 99 (52%) 27 (49%) 72 (54%) 0.56
Enrolled in AMPATH nutrition programme 33 (17%) 8 (14%) 24 (18%) 0.54
Food insecurity (reported ‘‘not enough food for
family’’)
135 (68%) 36 (64%) 98 (73%) 0.22
Reported difficulty with transportation to clinic 159 (84%) 44 (79%) 114 (86%) 0.23
aWHO classifies 2BWAZ ScoreB1 as ‘‘mild malnourishment’’; brows do not sum to 100% because participants could report multiple
persons who gave medicines.
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Among the study-administered measures, missed doses by
seven-day recall (range of Kappa statistic: 0.11 to 0.34) and
30-day recall (range: 0.10 to 0.37) had highest agreement
with the MEMS†. Missed doses by three-day recall (range:
0.05 to 0.25) had lower agreement with dichotomizedMEMS†,
and VAS even lower (range: 0.04 to 0.22). NVP (range: 0.15
to 0.24) and EFV (range: 0.20 to 0.36) drug concentration
also showed poor agreement with MEMS†. Caregiver-reported
missed doses of three-day, seven-day and 30-day recall sig-
nificantly increased in agreement with MEMS† from month 1
to month 2. Agreement was inconsistent thereafter, but gen-
erally remained higher than at month 1. Compared to other
measures, the clinician-administered adherence items had
the lowest agreement with MEMS† and did not illustrate
a significant improvement in agreement from month 1 to
month 2 (range: 0.06 to 0.16). Simple binary correlation
matrices between caregiver-reported missed doses revealed
high correlations between adherence by different recall
periods (three-day, seven-day, and 30-day), particularly for
caregiver-reported missed doses in the past three days and
in the past 30 days.
Predictors of adherence and treatment interruptions
In univariable analyses, factors associated with dichotomized
MEMS† adherence (Table 4) and treatment interruptions
(Table 5) were reported by caregivers as: problems in the
community, problems with giving the child medicines, med-
icines making the child sick, forgetting to give the medicines,
giving late doses and missing doses. In repeated-measures
logistic regression models, only caregiver-reported missed
doses in the last 30 days (OR 1.25, 95% CI 1.141.39), late
doses in the past seven days (OR 1.14, 95% CI 1.051.22)
and caregiver-reported problems with getting the child to
take ART (OR 1.10, 95% CI 1.011.20) were significantly
associated with dichotomized MEMS†. Caregiver-reported
difficulties related to community-level factors (OR 1.14, 95%
CI 1.021.27) and medication side effects (OR 1.12, 95% CI
Figure 1. Values: Mean adherence by multiple measures with 95% confident intervals
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1.011.25) were both significantly associated with treatment
interruptions of ]48 hours.
Discussion
In this cohort, adherence estimates by MEMS†, caregiver
reports and plasma drug concentrations varied widely. MEMS†
revealed high median rates of adherence (96% doses taken)
for this cohort, but lower rates of mean adherence (87%
of doses taken) and treatment interruptions were common.
Caregiver-reported seven-day and 30-day recall of any missed
doses to study personnel best correlated with MEMS† adher-
ence, although no adherence measure showed good agree-
ment with MEMS† and caregiver-reported missed doses to
clinicians during routine clinic visits had the poorest agree-
ment. Only the caregiver-reported problems with giving the
child ART, medication side effects and difficulties related to
community-level factors (particularly HIV-related stigma and
discrimination) were significantly associated with MEMS†
adherence. The relationship between caregiver-level HIV-
related stigma and paediatric adherence deserves further
Table 2. Adherence levels using multiple measures by visit
Adherence measure Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 Composite
MEMS† measures
Mean MEMS† doses taken (SD) 79% (26%) 86% (21%) 88% (19%) 89% (18%) 90% (19%) 89% (18%) 87%
Median MEMS† doses taken (IQR) 93%
(7396)
96%
(82100)
96%
(89100)
96%
(88100)
96%
(87100)
96%
(85100)
96%
Dichotomized MEMS† (]90% doses taken) 51% 64% 67% 67% 68% 68% 68%
Caregiver-reported measures
3-day: missed doses (% no missed doses) 94% 89% 92% 92% 95% 89% 92%
7-day: missed at least one dose in a day
(% no missed doses)
85% 85% 81% 86% 85% 79% 84%
7-day: missed all doses in a day (% no missed doses) 90% 92% 93% 94% 94% 91% 92%
7-day: late dose in a day (% no missed doses) 75% 74% 73% 72% 74% 73% 74%
30-day: missed doses (% no missed doses) 85% 80% 83% 82% 84% 81% 83%
Dichotomized VAS (% no missed morning doses) 96% 91% 95% 94% 93% 91% 93%
Dichotomized VAS (% no missed evening doses) 99% 99% 93% 96% 92% 91% 95%
Drug concentration measures
NVP plasma
Sub-therapeutic 15% 12% n/a
Optimal 34% 22%
Supra-therapeutic 51% 66%
EFV plasma
Sub-therapeutic 21% 32% n/a
Optimal 55% 46%
Supra-therapeutic 24% 22%
Routine AMPATH adherence
AMPATH Clinical Encounter Form (% no missed doses
in past 30 days)
98% 96% 95% 99% 96% 96% 97%
Table 3. Agreement between multiple measures and dichotomized MEMS†
Kappa statistics
Adherence measure Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6
3-day recall 0.05 0.25** 0.14* 0.14* 0.12* 0.23*
7-day recall 0.11 0.29** 0.21* 0.24** 0.34** 0.29**
30-day recall 0.10 0.33** 0.36** 0.28** 0.37** 0.30**
VAS 0.10 0.21 0.22* 0.08 0.04 0.20*
NVP drug concentration 0.15*   0.24**  
EFV drug concentration 0.36**   0.20  
AMPATH clinical encounter form 0.11* 0.13* 0.12* 0.06 0.16* 0.12*
*pB0.05; **p50.001.
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investigation, as a large study among African adults found that
individuals who reported more perceived HIV stigma were
more likely to report non-adherence to therapy [32].
Caregiver report is one of the most commonly used
adherence assessment methods for HIV-infected children in
resource-limited settings, but it likely overestimates adher-
ence to ART compared to other, more objective measures
like pill counts, pharmacy refill and electronic dose monitor-
ing [13]. We also found caregiver-reported adherence to be
significantly higher than adherence byMEMS†, and there was
generally poor agreement between caregiver-reported missed
doses and MEMS†. Our findings are consistent with work in
Zambia that found relatively poor agreement between
MEMS† and other adherence measures like caregiver-reported
missed doses, VAS and pill counts [33]. Other studies also
suggest that caregiver reports overestimate their child’s
adherence to ART and are not a valid adherence assessment
strategy [3437].
The longitudinal nature of this study allowed us to detect
changes in adherence. We found significantly improved
MEMS† adherence from month 1 to month 2, which was
sustained over the course of the study and is consistent with
a similar study in Zambia [33]. Our study was not designed
to measure an intervention effect, but the significant change
suggests that some aspect of the study procedures may have
improved adherence in this cohort. Further work is needed
to evaluate individual components of the study procedures
(e.g. discussing adherence and barriers with study staff,
reviewing MEMS† feedback, having medications in bottles
with MEMS† etc.) as an adherence intervention. Using
feedback from MEMS† as part of adherence counselling
has been shown to be effective in improving adherence in
randomized controlled trials among adults living with HIV
[38,39]; however, there are few data available for children.
Caregivers generally reported more missed doses to study
personnel after month 1, despite significantly higher MEMS†
adherence. This may suggest that caregivers became more
comfortable reporting non-adherence to study personnel
over time or that the use of MEMS† feedback encouraged
more reporting of non-adherence because caregivers knew
that the study team could see the number and timing of
missed doses by MEMS†. We hypothesize that the caregiver-
reported adherence to study staff became less biased and
more accurate as the study progressed. This trend was not
evident in caregiver-reported missed doses to clinicians, sug-
gesting that adherence assessments outside the patient-
provider relationship (e.g. using adherence counsellors or
case managers) may yield more accurate reporting of non-
adherence for children.
The frequent treatment interruptions of ]48 hours in
this cohort were concerning as interruptions increase risks
of drug resistance and viral rebound [4042]. Unplanned
Table 4. Items associated with dichotomized MEMS† non-adherence
Odds ratios (95% confidence interval)
Caregiver-reported factors Univariable model Multivariable modela
Forget to keep time when giving the medicines 1.07 (1.021.14) 1.05 (0.991.11)
Problems getting the child to take the medicines 1.15 (1.051.26) 1.09 (1.011.20)
Problems giving the child medicine because the child does not know reason for
medicines. (i.e. child does not know HIV status)
1.18 (1.021.37) 1.13 (0.971.32)
Missed doses in past 3 days 1.19 (1.071.32) 0.93 (0.811.06)
Missed doses in past 30 days 1.27 (1.171.39) 1.22 (1.091.38)
Missed all doses in a day in past 7 days 1.15 (1.041.25) 1.00 (0.871.15)
Missed one dose in a day in past 7 days 1.21 (1.111.32) 1.10 (0.971.24)
Took a dose more than one hour late in past 7 days 1.19 (1.101.28) 1.13 (1.061.22)
aMultivariable models adjusted for baseline gender, age (years) and duration on ART (years).
Table 5. Items associated with MEMS† treatment interruptions of ]48 hours
Odds ratios (95% confidence interval)
Caregiver-reported factors Univariable model Multivariable modela
Problems keeping time when giving the medicines 1.06 (1.011.11) 1.04 (0.991.10)
Problems getting the child to take the medicines 1.11 (1.031.21) 1.05 (0.961.16)
Medicines have made the child sick or ill 1.10 (1.011.20) 1.11 (1.011.24)
Difficulties in the community causing missed dose 0.94 (0.851.05) 1.13 (1.011.27)
Missed doses in past 30 days 1.09 (1.021.17) 1.05 (0.971.14)
Missed all doses in a day in past 7 days 1.13 (1.021.24) 1.05 (0.931.17)
Took a dose more than one hour late in past 7 days 1.08 (1.021.15) 1.05 (0.981.11)
aMultivariable models adjusted for baseline gender, age (years) and duration on ART (years).
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treatment interruptions may be more likely in LMICs due
to barriers like inconsistent drug supplies, the financial costs
of drugs and transportation to clinic, food insecurity and
HIV stigma [19]. AMPATH did not have any major pharmacy
stock-outs during the study period; however, malnutrition
and poverty were high in this cohort. Previous qualitative
work among caregivers of HIV-infected children in this setting
suggested that HIV stigma and HIV disclosure pose significant
challenges to ART adherence [43]. The association between
caregiver-reported community-level factors (e.g. stigma) and
treatment interruptions in this study supports the idea that
social factors impact adherence. Children’s knowledge of
their own HIV status may impact adherence, but we did not
find a significant association between disclosure and adher-
ence. At least 25% of caregivers reported giving a late dose
in the past week at monthly visits, but late doses were
not associated with treatment interruptions, suggesting that
different factors may affect interruptions versus delays. For
example, in previous qualitative work in this setting, we
found that children experience treatment interruptions when
traveling over the weekend, whereas delays are experienced
when caregivers arrive home late at night from work or
visitors are in the home [43].
Collecting plasma drug concentrations was a unique aspect
of this study and is not often available in this setting.We found
that significant numbers of children had sub-therapeutic and
supra-therapeutic drug levels. This is concerning as sub-
therapeutic levels are associated with drug resistance and
virologic failure, while supra-therapeutic levels are associated
with increased frequency and severity of side effects in
adults living with HIV [4448]. Children on EFV were more
likely to have sub-therapeutic levels than children on NVP,
whereas children on NVP were more likely to have supra-
therapeutic levels; in fact, more than half of children on NVP
had supra-therapeutic drug levels. Drug concentrations did
not correlate well with MEMS† adherence, which may be
due to several factors. First, MEMS† adherence was calcu-
lated for all doses taken between study visits (approximately
one month), whereas drug concentrations only indicate adher-
ence within hours to days. Drug concentrations would likely
correlate better with MEMS† if MEMS† were restricted to
doses taken in the 2-3 days prior. Second, drug concentrations
may be influenced by the dearth of pharmacokinetic data
for antiretroviral drugs in children, especially in sub-Saharan
Africa [49,50]. AMPATH follows standard paediatric dosing
recommendations, but it is possible that these dosing guide-
lines are not optimal and lead to sub-therapeutic or supra-
therapeutic drug concentrations, even if the patient is
adherent. Inappropriate drug levels may reflect problems
with dosing recommendations more than adherence diffi-
culties. A study among children on EFV-based regimens in
South Africa found that 40% had sub-therapeutic drug levels
(B1.0 mg/mL), while another study in South Africa reported
median sub-therapeutic levels of EFV in 17% of children at
one, three and six months of follow-up [51,52]. The propor-
tion of children in our cohort with supra-therapeutic drug
levels also deserves further consideration, particularly be-
cause caregiver-reported medication side effects were sig-
nificantly associated with treatment interruptions. Studies
in Malawi, Zambia and Germany have reported high rates of
supra-therapeutic drug levels in children, although not as high
as those found in our study [53,54]. More pharmacokinetic
studies among African paediatric populations are needed to
ensure that dosing recommendations are appropriate.
Several limitations of this study deserve consideration.
First, this study employed convenience sampling that intro-
duces potential selection bias and, in this case, might have
led to children who had excellent adherence or very low
adherence being more likely to enrol. Regardless of baseline
adherence levels and whether they were higher or lower
than those of the general AMPATH paediatric population, we
still should have been able to detect significant associations
between adherence and various clinical, demographic and
social factors. Second, the intensive study procedures likely
affected adherence over the course of the study; however,
we could not evaluate these effects. Third, electronic drug
monitoring is typically reserved for research settings, as the
technology is often too expensive for routine monitoring.
Furthermore, MEMS† has important limitations (e.g. patients
removing more than one dose of medicines or switching
between bottles) that have not been adequately explored in
this setting [55,56]. Fourth, we did not have access to viral
load testing for this cohort of patients. Virological suppres-
sion is considered the most important outcome of adherence
to therapy [57]; however, due to funding constraints, viral
loads were unavailable. Finally, our sample of 191 children
was relatively small, and follow-up time was relatively short.
Children were on first-line ART for a mean of 2.3 years and
most were entering early adolescence, so issues of treatment
fatigue and disclosure of HIV status may present additional
barriers to adherence in the coming years [58]. Furthermore,
this study took place at the largest, most urban clinic within
AMPATH, and so our findings may not be generalizable for
smaller or more rural clinics. Nonetheless, this sample pro-
vides detailed adherence measurements for a sub-Saharan
African paediatric population and provides preliminary sup-
port for validating routine adherence monitoring in paediatric
populations in LMICs, as well as pointing to electronic moni-
toring with feedback as a potential adherence intervention.
Conclusions
We found that caregiver-reported missed doses overestimate
children’s adherence to ART compared to electronic dose moni-
toring. Despite high rates of adherence by caregiver report,
missed and late doses, treatment interruptions of more than
48 hours and sub-therapeutic drug levels were common.
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